| __timestamp | Bausch Health Companies Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 246000000 | 79696000 |
| Thursday, January 1, 2015 | 582800000 | 93236000 |
| Friday, January 1, 2016 | 455000000 | 150842000 |
| Sunday, January 1, 2017 | 366000000 | 150643000 |
| Monday, January 1, 2018 | 414000000 | 150252000 |
| Tuesday, January 1, 2019 | 471000000 | 140804000 |
| Wednesday, January 1, 2020 | 452000000 | 34236000 |
| Friday, January 1, 2021 | 465000000 | 35672000 |
| Saturday, January 1, 2022 | 529000000 | 66607000 |
| Sunday, January 1, 2023 | 604000000 | 76363000 |
| Monday, January 1, 2024 | 79048000 |
Data in motion
In the ever-evolving landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Bausch Health Companies Inc. and Halozyme Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment.
From 2014 to 2023, Bausch Health consistently allocated a significant portion of its resources to R&D, with expenditures peaking in 2023 at approximately 604 million USD. This represents a 145% increase from their 2014 spending. In contrast, Halozyme's R&D spending showed a more fluctuating pattern, with a notable peak in 2016 and a subsequent decline, ending 2023 with a 4% decrease from their 2014 levels.
These trends highlight Bausch Health's steady commitment to innovation, while Halozyme's variable spending may reflect strategic shifts or external challenges. Understanding these patterns offers valuable insights into each company's strategic priorities and market positioning.
Eli Lilly and Company or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Investment: Eli Lilly and Company vs Bausch Health Companies Inc.
Research and Development Investment: Sanofi vs Bausch Health Companies Inc.
Research and Development: Comparing Key Metrics for argenx SE and Bausch Health Companies Inc.
Who Prioritizes Innovation? R&D Spending Compared for Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc.
R&D Spending Showdown: Incyte Corporation vs Bausch Health Companies Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and MannKind Corporation
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Corcept Therapeutics Incorporated and Bausch Health Companies Inc.
Research and Development: Comparing Key Metrics for CRISPR Therapeutics AG and Bausch Health Companies Inc.
Analyzing R&D Budgets: Veracyte, Inc. vs Bausch Health Companies Inc.
Who Prioritizes Innovation? R&D Spending Compared for Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.